Natera
 | This article may have been created or edited in return for undisclosed payments, a violation of Wikipedia's terms of use. It may require cleanup to comply with Wikipedia's content policies, particularly neutral point of view. (June 2021) |
 | |
| Formerly | Gene Security Network, Inc. (2004–2012) |
|---|---|
| Company type | Public |
| |
| Industry | Genetic testing |
| Founded | 2004 |
| Founders |
|
| Headquarters | Austin, Texas, U.S. |
Key people |
|
| Revenue |  US$797 million (2022) |
 US$−541 million (2022) | |
| US$−548 million (2022) | |
| Total assets | US$1.39 billion (2022) |
| Total equity | US$706 million (2022) |
Number of employees | 3,018 (2022) |
| Website | natera |
| Footnotes / references [1] | |
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA (cfDNA) testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments (CLIA) in San Carlos, California and Austin, Texas.
History
[edit]Natera (previously Gene Security Network) was founded by Matthew Rabinowitz and Jonathan Sheena in 2004.[2] Natera launched its first product, the Spectrum preimplantation genetic test, in 2009.
In 2010, the company introduced the Anora miscarriage (POC) test. Natera's advanced carrier screening test, Horizon, launched in 2012. The following year, 2013, Natera launched the Panorama non-invasive prenatal test (NIPT).
In July 2015, Natera conducted an initial public offering of common stock at a price of $18.00 per share. The shares trade on the Nasdaq Global Select Market under the symbol "NTRA."[3]
In 2017, Natera launched the Vistara single-gene NIPT. That same year, Natera introduced the Signatera molecular residual disease (MRD) test for research use only. The Signatera CLIA test was introduced for clinical use in 2019.
In 2018 Natera paid a $11 million fine to the department over allegations of improper billing and sales of Panorama to federal Healthcare services between the years of 2013 to 2016.[4]
Natera launched the Prospera dd-cfDNA transplant assessment test in 2019, and the Renasight kidney gene panel and the Empower hereditary cancer test in 2020.
As of May 2021, Natera has performed over 3 million cell-free DNA tests.[5] Natera's technology has also been written about in over 200 peer-reviewed journals and publications,[6] including Nature, Science Magazine, and the Journal of Clinical Oncology.
Products and services
[edit]Women's health
[edit]The Panorama NIPT is the only single-nucleotide polymorphism (SNP)-based NIPT. The test analyzes fetal DNA found in the mother's blood to reveal a baby's risk for genetic disorders such as Down syndrome (trisomy 21) and Edwards syndrome (trisomy 18) as early as nine weeks.[7] Panorama also tests for unique microdeletions[8] and is the only test that can detect zygosity and fetal sex in twins.[9]
Natera also offers Horizon, a carrier-screening test that uses next-generation sequencing to provide carrier status for up to 274 genetic conditions. Additionally, Natera offers the Anora products of conception (POC) miscarriage test, the Spectrum preimplantation genetic screening and diagnosis test, and the Vistara single-gene prenatal screening test. In 2020, Natera launched Empower, a hereditary cancer test that screens for up to 53 genes associated with increased risk for common hereditary cancers.
Oncology
[edit]Signatera is the first circulating tumor DNA (ctDNA) assay built for molecular residual disease (MRD) detection and cancer recurrence monitoring.[10] In 2020, Signatera received the CE Mark, as well as final Medicare coverage in stage II-III colorectal cancer and draft coverage in immunotherapy response monitoring. Signatera has been clinically validated to detect colorectal cancer recurrence up to 16.5 months in advance of radiologic imaging[11] and early-stage breast cancer up to two years earlier than imaging.[12]
Organ health
[edit]The Prospera test is the first assay with high sensitivity to both T-cell-mediated and antibody-mediated rejection.[13][14] In December 2019, the test received final Medicare coverage. In 2020, Natera launched Renasight, a test to determine if there is a genetic cause for an individual's kidney disease and if there may be other at-risk relatives.
Constellation
[edit]Natera offers a cloud-based bioinformatics platform called Constellation, allowing laboratories to access and use Natera's technology in their own facilities. Constellation is currently only available outside of the United States.
References
[edit]- ^ "Natera, Inc. 2022 Annual Report (Form 10-K)". U.S. Securities and Exchange Commission. 2023-03-01.
- ^ Olen, Melanie (2017-05-03). "How a Family Tragedy Inspired This Founder to Help Pregnant Women". Inc.
- ^ "NTRA Real-Time Quotes". Nasdaq.
- ^ "California Genetic Testing Service Pays $11 Million To Resolve False Claims Allegations". www.justice.gov. 2018-03-09. Retrieved 2022-03-21.
- ^ "Natera Announces the Validation and Launch of the Prospera™ Heart Transplant Assessment Test". Natera. Retrieved 2022-01-14.
- ^ "Natera Announces Significant Milestone with 200+ Peer-Reviewed Publications". Natera. Retrieved 2024-07-04.
- ^ "Natera Launches Noninvasive Prenatal Test; Quest to Offer in Limited Areas by March, Nationwide in April". GenomeWeb. 20 February 2013. Retrieved 2021-02-21.
- ^ Wapner, Ronald J.; Babiarz, Joshua E.; Levy, Brynn; Stosic, Melissa; Zimmermann, Bernhard; Sigurjonsson, Styrmir; Wayham, Nicholas; Ryan, Allison; Banjevic, Milena; Lacroute, Phil; Hu, Jing; Hall, Megan P.; Demko, Zachary; Siddiqui, Asim; Rabinowitz, Matthew; Gross, Susan J.; Hill, Matthew; Benn, Peter (2015-03-01). "Expanding the scope of noninvasive prenatal testing: detection of fetal microdeletion syndromes". American Journal of Obstetrics and Gynecology. 212 (3): 332.e1–332.e9. doi:10.1016/j.ajog.2014.11.041. ISSN 0002-9378. PMID 25479548.
- ^ Norwitz, Errol R.; McNeill, Gabriel; Kalyan, Akshita; Rivers, Elizabeth; Ahmed, Ebad; Meng, Ling; Vu, Phikhanh; Egbert, Melissa; Shapira, Marlene; Kobara, Katie; Parmar, Sheetal (July 2019). "Validation of a Single-Nucleotide Polymorphism-Based Non-Invasive Prenatal Test in Twin Gestations: Determination of Zygosity, Individual Fetal Sex, and Fetal Aneuploidy". Journal of Clinical Medicine. 8 (7): 937. doi:10.3390/jcm8070937. PMC 6679081. PMID 31261782.
- ^ "CANCER GENETICS". Nesiller Genetik. Retrieved 2023-07-25.
- ^ Reinert, Thomas; Henriksen, Tenna Vesterman; Christensen, Emil; Sharma, Shruti; Salari, Raheleh; Sethi, Himanshu; Knudsen, Michael; Nordentoft, Iver; Wu, Hsin-Ta; Tin, Antony S.; Heilskov Rasmussen, Mads (2019-08-01). "Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to III Colorectal Cancer". JAMA Oncology. 5 (8): 1124–1131. doi:10.1001/jamaoncol.2019.0528. ISSN 2374-2437. PMC 6512280. PMID 31070691.
- ^ Coombes, Raoul Charles; Page, Karen; Salari, Raheleh; Hastings, Robert K.; Armstrong, Anne; Ahmed, Samreen; Ali, Simak; Cleator, Susan; Kenny, Laura; Stebbing, Justin; Rutherford, Mark (2019-07-15). "Personalized Detection of Circulating Tumor DNA Antedates Breast Cancer Metastatic Recurrence". Clinical Cancer Research. 25 (14): 4255–4263. doi:10.1158/1078-0432.CCR-18-3663. hdl:2381/43904. ISSN 1078-0432. PMID 30992300.
- ^ Sigdel, Tara K.; Archila, Felipe Acosta; Constantin, Tudor; Prins, Sarah A.; Liberto, Juliane; Damm, Izabella; Towfighi, Parhom; Navarro, Samantha; Kirkizlar, Eser; Demko, Zachary P.; Ryan, Allison (January 2019). "Optimizing Detection of Kidney Transplant Injury by Assessment of Donor-Derived Cell-Free DNA via Massively Multiplex PCR". Journal of Clinical Medicine. 8 (1): 19. doi:10.3390/jcm8010019. PMC 6352163. PMID 30583588.
- ^ Bloom, Roy D.; Bromberg, Jonathan S.; Poggio, Emilio D.; Bunnapradist, Suphamai; Langone, Anthony J.; Sood, Puneet; Matas, Arthur J.; Mehta, Shikha; Mannon, Roslyn B.; Sharfuddin, Asif; Fischbach, Bernard (2017-07-01). "Cell-Free DNA and Active Rejection in Kidney Allografts". Journal of the American Society of Nephrology. 28 (7): 2221–2232. doi:10.1681/ASN.2016091034. ISSN 1046-6673. PMC 5491290. PMID 28280140.